▲ +612.47% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Allena Pharmaceuticals in the last 3 months. The average price target is $9.33, with a high forecast of $18.00 and a low forecast of $4.00. The average price target represents a 612.47% upside from the last price of $1.31.
The current consensus among 7 investment analysts is to buy stock in Allena Pharmaceuticals.
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.